Original Research
Published on 29 Jun 2017
The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study
in Cancer Molecular Targets and Therapeutics
Frontiers in Pharmacology
doi 10.3389/fphar.2017.00413
- 6,274 views
- 4 citations

